4.7 Article

The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality

Journal

BLOOD
Volume 99, Issue 10, Pages 3493-3499

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.V99.10.3493

Keywords

-

Categories

Funding

  1. NHLBI NIH HHS [R37 HL56067] Funding Source: Medline
  2. NIAID NIH HHS [P01 AI 35225, R01 AI34495] Funding Source: Medline

Ask authors/readers for more resources

Immune regulatory CD4(+)CD25(+) cells play a vital role In the Induction and maintenance of self-tolerance and the prevention of autoimmunity. Recently, CD4 CD25(+) cells have been shown to be required for the ex vivo induction of tolerance to alloantigen via costimulatory blockade and to inhibit allogeneic skin graft rejection. Data presented here demonstrate that CD4(+)CD25(+) cells play an important role in graft-versus-host disease (GVHD) generation. Depletion of CN(+)CD25(+) cells from the donor T-cell inoculum or In vivo CD25-depletlon of the recipient before transplantation resulted in Increased GVHD mediated by CD4(+) or whole T cells in several strain combinations irrespective of the total body irradiation conditioning regime. The infusion of freshly purified donor CD4(+)CD25(+) cells modestly inhibited GVHD when administered in equal numbers with whole CD4(+) cells. Because CD4(+)CD25(+) cells only account for 5% to 10% of the total CD4(+) population, the administration of high numbers of fresh donor CD4(+)CD25(+) cells may not be clinically practical. However, we found that large numbers of CD4(+)CD25(+) cells can be obtained by ex vivo activation and expansion. Cultured CD4(+)CD25(+) cells, administered in equal numbers with CD4(+) T cells or CD25-depleted whole T cells, resulted in significant inhibition of rapidly lethal nGVHD. To our knowledge, this study is the first to demonstrate that activated, cultured CD4(+)CD25(+) cells can offer substantial protection in a relevant in vivo animal model of disease. These data have important ramifications for clinical bone marrow and solid organ transplantation. CD4(+)CD25(+) cells warrant consideration as an exciting new modality of cellular therapy for the inhibition of undesirable autologous and allogeneic responses. (C) 2002 by The American Society of Hematology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available